PATENT CLAIM ANALYSIS

Application Number: 16240368
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "374000"]

Abstract:
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A 2  receptor antagonist.

Claim (Index 1):
A method of treating Duchenne muscular dystrophy in a patient in need of treatment thereof, comprising administering a therapeutically effective amount of a thromboxane A 2  receptor antagonist to the patient, wherein the thromboxane A 2  receptor antagonist is [1S-(1\u03b1,2\u03b1,3\u03b1,4\u03b1)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 99.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15592727', '14715143', '16004666', '15608507', '14391484']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7881901783017312
- 35 USC 102 Novelty (BERT): 0.6659380089322133
- Combined Prediction Score: 0.7759649613647794
- Mean Citation Score: 474.704658
- Max Citation Score: 725.87805
- Similarity Product: 599.4196245666236

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test